2018-11-08T10:54:12-06:00 2017-12-31 521853933 JONES MARESCA & MCQUADE PA 10500 LITTLE PATUXENT PARKWAY SUITE 770 COLUMBIA MD 21044 990 2017-01-01 522320756 ACCELERATE BRAIN CANCER CURE INC ACCE 2024193140 1717 RHODE ISLAND AVENUE NW NO 700 WASHINGTON DC 20036 MAX WALLACE PRESIDENT AND CEO 2024193140 2018-11-08 1 LISA CHEIFETZ P01444196 4108840220 64.88.174.3 2018-11-08 11:28:28 ES P 0087580C7340B0612ABF44AF1D415F2C3C4A590E 0087580C7340B0612ABF44AF1D415F2C3C4A590E 2017 2019-02-21 02:37:17Z MAX WALLACE 1717 RHODE ISLAND AVENUE NW NO 700 WASHINGTON DC 20036 2325542 0 X WWW.ABC2.ORG X 2001 DC ACCELERATE BRAIN CANCER CURE HAS A SINGLE FOCUS-TO HASTEN THE DISCOVERY OF A CURE FOR BRAIN CANCER. 8 8 7 300 0 0 1961022 1772747 0 0 12328 9924 0 0 1973350 1782671 911118 715237 0 0 889986 967720 0 0 763184 435062 452089 2236166 2135046 -262816 -352375 3356332 2896513 515640 408196 2840692 2488317 THE PRIMARY OBJECTIVE OF ACCELERATE BRAIN CANCER CURE, INC. IS TO ACCELERATE PROGRESS IN WHAT HAS BEEN AN UNDERSERVED FIELD OF RESEARCH; THE ORGANIZATION AIMS TO RAISE AWARENESS ABOUT BRAIN CANCER AND HELP MOBILIZE CRITICAL SCIENTIFIC RESEARCH THROUGH RESEARCH GRANTS. 0 0 1047184 715237 ACCELERATE BRAIN CANCER CURE, INC. (ABC2) BELIEVES A FOCUSED AND AGGRESSIVE ENTREPRENEURIAL MODEL WILL INCREASE THE NUMBER OF THERAPIES DISCOVERED AND ENABLE THOSE THERAPIES TO BE AVAILABLE TO DOCTORS AND PATIENTS MORE QUICKLY. ABC2 PROVIDES RESEARCHERS WITH THE PIVOTAL SUPPORT THEY NEED TO MAKE CRITICAL BREAKTHROUGHS. IT FUNDS TRANSLATIONAL RESEARCH AIMED AT FINDING THE FASTEST POSSIBLE ROUTE TO A CURE. ABC2 SUPPORTS A RANGE OF MEDICAL RESEARCH ORGANIZATIONS. 1047184 1 1 0 0 0 0 0 0 0 0 1 0 0 0 1 1 1 0 0 0 0 0 0 0 1 0 0 1 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 17 0 1 7 1 0 0 0 0 0 0 0 0 0 0 X 8 8 1 0 0 0 0 0 0 1 1 0 0 0 1 1 1 1 1 0 0 0 CA NY X THE ORGANIZATION 2024193140 1717 RHODE ISLAND AVENUE NW NO 700 WASHINGTON DC 20036 STACEY CASE CO-FOUNDER 1.00 X 0 0 0 STEVE CASE CHAIRMAN & CO-FOUNDER 1.00 X X 0 0 0 NANCY PFUND MEMBER 1.00 X 0 0 0 DAVID COLE MEMBER 1.00 X 0 0 0 JEAN CASE CO-FOUNDER 1.00 X 0 0 0 DOUG HOLLADAY MEMBER 1.00 X 0 0 0 JONATHAN WEINBERG MEMBER 1.00 X 0 0 0 GARY WIMMER MEMBER 1.00 X 0 0 0 DAVID SANDAK VP, SECRETARY/TREASURER 40.00 X 157664 0 36050 MAX WALLACE PRESIDENT AND CEO 40.00 X 305586 0 15095 463250 0 51145 2 0 1 0 0 1051925 720822 28864 1772747 6629 6629 177904 174609 3295 3295 3295 368262 1051925 368262 0 1782671 3295 0 6629 X 715237 715237 514395 92818 130782 290795 374893 68035 93391 213467 12991 1404 11587 15969 3143 5266 7560 49472 7355 11826 30291 720 720 270824 90991 50937 128896 22083 2761 9268 10054 15275 3600 8075 3600 64441 30056 1203 33182 29176 18035 2128 9013 3984 3984 20473 14648 5825 LICENSE AND REGISTRATIO 15577 505 489 14583 WEBSITE & AV 9536 100 9436 2135046 1047184 324678 763184 2966834 2551650 275637 303684 104975 33147 43554 35553 8869 8001 17 31 3356332 2896513 72153 86320 380835 250000 62652 71876 515640 408196 X 2565055 2184101 275637 304216 2840692 2488317 3356332 2896513 -352375 0 X X 0 1 X 1 0 X 3168066 2154714 2575366 1961022 1773551 11632719 3168066 2154714 2575366 1961022 1773551 11632719 1112810 10519909 215 649 2017 1732 6629 11242 11643961 0.90350 0.90050 X 43554 35553 8001 8001 DUE TO AFFILIATED ENTRY 71876 71876 X 2244865 93932 368262 462194 1782671 0 1782671 2597240 93932 368262 462194 2135046 0 2135046 PART X, LINE 2: ABC2 BELIEVES THAT IT HAS APPROPRIATE SUPPORT FOR ANY TAX POSITIONS TAKEN, AND AS SUCH, DOES NOT HAVE ANY UNCERTAIN TAX POSITIONS THAT ARE MATERIAL TO THE FINANCIAL STATEMENTS OR THAT WOULD HAVE AN EFFECT ON ITS TAX-EXEMPT STATUS. THERE ARE NO UNRECOGNIZED TAX BENEFITS OR LIABILITIES THAT NEED TO BE RECORDED. PART XI, LINE 2D - OTHER ADJUSTMENTS: DIRECT FUNDRAISING EXPENSES 368,262. PART XII, LINE 2D - OTHER ADJUSTMENTS: DIRECT FUNDRAISING EXPENSES 368,262. RACE FOR HOPE FUNDRAISING EVENT-DC 931123 795120 136003 136003 CITY EVENTS 105764 105764 6 383300 151041 232259 232259 1420187 1051925 368262 136003 232259 368262 0 1 FLORIDA CENTER FOR BRAIN TUMOR RESEARCH - UNIVERSITY OF FLORIDA HEALTH BOX 100265 UNIVERSITY OF FLORIDA GAINESVILLE FL 32610 591943502 501(C)(3) 100000 TO SUPPORT FCBTR'S 2017 GRANTEES SYAPSE INC 101 UNIVERSITY AVENUE SUITE 230 PALO ALTO CA 94301 263457459 100000 TO USE SYAPSE'S SOFTWARE TO INTERPRET RAW GENOMIC DATA FOR BRAIN CANCER CLINICAL RESEARCH PURPOSES. BROAD INSTITUTE 415 MAIN STREET CAMBRIDGE MA 02142 263428781 501(C)(3) 131955 DFCI-10 GBM CASES FOR CLIA SOMATIC WES COHEN VETERANS BIOSCIENCE INC 810 VERMONT AVE NW WASHINGTON DC 20420 471981973 501(C)(3) 125000 TO PROVIDE DATA AND KNOWLEDGE NECESSARY TO DEVELOP A SAMRT SYSTEM DESIGNED TO COLLECT AND ANALYZE DATA CAPTURED BY WEARABLE SMART DEVISES. UNIVERSITY OF FLORIDA PO BOX 100265 MBI ROOM L1-181 GAINESVILLE FL 32605 596002052 501(C)(3) 150000 PATENTS JOHNS HOPKINS UNIVERSITY - MONTGOMERY 9601 MEDICAL CENTER DR ROCKVILLE MD 20850 520595110 501(C)(3) 8282 PATENTS DANA FARBER CANCER INSTITUTE 450 BROOKLINE AVENUE BOSTON MA 02115 042263040 501(C)(3) 100000 INDIVIDUALIZED SCREENING TRIAL OF INNOVATIVE GLIOBLASTOMA THERAPY (INSIGHT) 6 1 PART I, LINE 2: ABC2 CLOSELY MONITORS THE PROGRESS OF THE RESEARCHERS IT FUNDS THROUGH ITS GRANT PROGRAM. THE ORGANIZATION REQUIRES SCIENTIFIC PROGRESS REPORTS AND COMPLETE FINANCIAL ACCOUNTING OF EXPENDITURES BEFORE RELEASING ADDITIONAL FUNDS AS WELL AS FINAL GRANT REPORTS INCLUDING FINANCIAL REPORTS. IN ADDITION, ABC2 HOLDS AN ANNUAL SCIENTIFIC MEETING AT WHICH TIME CERTAIN GRANTEES PRESENT THEIR PROGRESS. X X 0 0 0 0 0 0 0 0 0 DAVID SANDAK VP, SECRETARY/TREASURER 157664 0 0 0 0 0 6701 0 29349 0 193714 0 0 0 MAX WALLACE PRESIDENT AND CEO 305586 0 0 0 0 0 0 0 15095 0 320681 0 0 0 X 4 28864 FAIR MARKET VALUE 0 0 0 PART I, COLUMN (B): THE ORGANIZATION REPORTS THE NUMBER OF CONTRIBUTIONS FORM 990, PART VI, SECTION A, LINE 2 STEPHEN CASE, CHAIRMAN & BOARD MEMBER AND JEAN CASE, BOARD MEMBER ARE CO-FOUNDERS AND SPOUSES. STACEY CASE, BOARD MEMBER AND CO-FOUNDER, IS THE SISTER-IN-LAW OF STEPHEN CASE. THESE BOARD MEMBERS ALSO HAVE BUSINESS RELATIONSHIPS. FORM 990, PART VI, SECTION B, LINE 11B MAX WALLACE, THE CHIEF EXECUTIVE OFFICER OF ACCELERATE BRAIN CANCER CURE, INC. REVIEWS AND SIGNS THE 990. THE 990 IS ALSO REVIEWED BY THE FINANCE COMMITTEE BEFORE IT IS FILED. FORM 990, PART VI, SECTION B, LINE 12C THE BOARD OF DIRECTORS REVIEWS THE CONFLICT OF INTEREST POLICY AT ITS ANNUAL BOARD MEETING. INDEPENDENCE IS ALSO CONFIRMED PRIOR TO THE AWARDING OF ANY EXPENDITURE RESPONSIBILITY GRANT. FORM 990, PART VI, SECTION B, LINE 15 THE CHIEF EXECUTIVE OFFICER JOINED THE ORGANIZATION IN 2008. AS PART OF THE EXECUTIVE SEARCH PROCESS AN INDEPENDENT SEARCH FIRM PERFORMED AN INDUSTRY COMPENSATION ANALYSIS. THE LAST COMPENSATION REVIEW TOOK PLACE ON DECEMBER 2015. THE ORGANIZATION HAD NO KEY EMPLOYEES. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANICAL STATEMENTS AVAILABLE FOR PUBLIC INSPECTION UPON REQUEST. FORM 990, PART IX, LINE 11G CONSULTING & PROFESSIONAL FEES: PROGRAM SERVICE EXPENSES 90,991. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 128,896. TOTAL EXPENSES 219,887. HONORARIA: PROGRAM SERVICE EXPENSES 0. MANAGEMENT AND GENERAL EXPENSES 50,937. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 50,937. FORM 990, PART XII, LINE 2C THIS PROCESS HAS NOT CHANGED FROM THE PRIOR YEAR.